Market
Will the FDA approve a drug based on the new molecule for Alzheimer's by end of 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements or press releases
Story
Scientists Discover Molecule to Restore Cognitive Function and Potentially Reverse Dementia in Early Alzheimer's Disease
Jan 26, 2025, 01:16 AM
Recent research has unveiled a promising molecule that may restore cognitive function in early Alzheimer's disease. This discovery could facilitate the development of drugs aimed at slowing or potentially reversing dementia, according to the authors of the study. Additional findings highlight the loss of signaling fidelity between astrocyte endfeet and adjacent cerebral arterioles in an amyloid mouse model of Alzheimer's. Other studies have focused on the unique cellular neighborhood of the murine leptomeninges-cortical brain interface, as well as misclassification in memory modification in the AppNL-G-F knock-in mouse model of Alzheimer's disease. These insights contribute to a deeper understanding of the disease's mechanisms and potential therapeutic targets.
View original story
Similar markets
Pending • 25%
Unclear • 25%
No • 25%
Yes • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Rejection • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Rejected • 25%
Approved • 25%
Withdrawn by Axsome • 25%
Conditional Approval • 25%
Yes • 50%
No • 50%
